Cowen downgraded shares of Myriad Genetics (NASDAQ:MYGN) from an outperform rating to a market perform rating in a research report released on Tuesday, Benzinga reports. Cowen currently has $26.64 price target on the stock.
Other analysts have also issued reports about the company. BidaskClub lowered Extraction Oil & Gas from a hold rating to a sell rating in a research report on Saturday, May 4th. Zacks Investment Research lowered First Merchants from a hold rating to a sell rating in a research report on Monday, July 1st. Barclays set a $18.00 target price on Summit Materials and gave the stock a hold rating in a research report on Friday, June 14th. Needham & Company LLC reaffirmed a strong-buy rating and set a $32.00 target price on shares of Myriad Genetics in a research report on Tuesday, May 14th. They noted that the move was a valuation call. Finally, ValuEngine lowered Valero Energy from a hold rating to a sell rating in a research report on Wednesday, May 8th. Three analysts have rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Myriad Genetics has an average rating of Hold and an average target price of $37.74.
NASDAQ:MYGN opened at $25.72 on Tuesday. The firm has a 50-day moving average of $25.18. The company has a quick ratio of 2.86, a current ratio of 3.15 and a debt-to-equity ratio of 0.24. Myriad Genetics has a 12 month low of $22.07 and a 12 month high of $50.44. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of 18.38, a PEG ratio of 1.33 and a beta of 0.82.
Large investors have recently bought and sold shares of the stock. Pearl River Capital LLC grew its stake in Myriad Genetics by 154.9% in the first quarter. Pearl River Capital LLC now owns 882 shares of the company’s stock worth $30,000 after purchasing an additional 536 shares in the last quarter. Investors Research Corp acquired a new position in Myriad Genetics in the first quarter worth about $46,000. Financial Gravity Wealth Inc. acquired a new position in Myriad Genetics in the first quarter worth about $56,000. Nisa Investment Advisors LLC grew its stake in Myriad Genetics by 625.0% in the first quarter. Nisa Investment Advisors LLC now owns 2,320 shares of the company’s stock worth $77,000 after purchasing an additional 2,000 shares in the last quarter. Finally, QS Investors LLC grew its stake in Myriad Genetics by 17,692.3% in the fourth quarter. QS Investors LLC now owns 4,626 shares of the company’s stock worth $135,000 after purchasing an additional 4,600 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
See Also: How to Trade Using Analysts Ratings
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.